Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
Zenas BioPharma (ZBIO) will present at three upcoming healthcare investor conferences in September 2026.
Rhea-AI Summary
Zenas BioPharma (ZBIO) will present at three upcoming healthcare investor conferences in September 2026.
Management is scheduled to speak at the Citi Biopharma Back to School Conference on September 9 at 4:20 p.m. ET, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 at 4:05 p.m. ET, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16 at 8:00 a.m. ET. Live webcasts and replays will be available on the company’s website under “Events and Presentations.”
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 18 | Inducement grant announcement | Neutral | -2.1% | Granted 11,000 restricted stock units to newly hired employees under the 2026 Inducement Plan. |
| Aug 13 | Second-quarter earnings | Negative | -6.7% | Reported a $111.5 million net loss despite regulatory and pipeline progress. |
| Jul 17 | Inducement grant announcement | Neutral | +4.0% | Granted options covering 35,750 shares and 79,050 restricted stock units. |
| Jun 17 | Inducement grant announcement | Neutral | +6.5% | Granted options covering 100,000 shares and 78,075 restricted stock units. |
| Jun 11 | Investor presentation announcement | Neutral | +11.5% | Announced an on-demand presentation at the H.C. Wainwright Neuro Perspectives Summit. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior presentation and inducement-grant announcements were followed by positive moves, while the latest earnings release was followed by a negative move.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences:
- Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ET
- Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET
- H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 8:00 a.m. ET
Live webcasts and archived replays of the Company’s presentations can be accessed under “Events and Presentations” in the Investor & Media Relations section of the Zenas BioPharma website.
About Zenas BioPharma, Inc.
Zenas is a clinical-stage global biopharmaceutical company focused on the development and commercialization of therapies for autoimmune diseases and inflammatory conditions. Zenas combines our experienced leadership team with a disciplined global product candidate acquisition approach to identify, acquire and develop product candidates with the potential to deliver clinically meaningful benefits to patients. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb to inhibit the activity of B cells implicated in many autoimmune diseases without depleting them. Zenas believes that the unique mechanism of action of obexelimab and its self-administered, subcutaneous injection regimen may enable sustained control across multiple chronic autoimmune diseases. Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor. Orelabrutinib’s mechanism of action targets pathogenic B cells not only in the periphery but also within the CNS. Additionally, it directly modulates macrophages and microglial cells in the CNS, with the potential to address compartmentalized inflammation and disease progression in MS. Zenas’ earlier stage programs include ZB021, a novel, potentially best-in-class, oral, IL-17AA/AF inhibitor, ZB022, a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor, and ZB014, a preclinical, half-life extended anti-CD19 and FcγRIIb monoclonal antibody. For more information about Zenas BioPharma, please visit https://zenasbio.com/ and follow us on LinkedIn.
The Zenas BioPharma word mark, logo mark, and the “lightning bolt” design are trademarks of Zenas BioPharma, Inc. or its affiliated companies. All rights reserved.
Contacts:
Investors:
Argot Partners
Zenas@argotpartners.com
Media:
Kristin Ainsworth
SVP, U.S. Commercial Strategy & Corporate Affairs
612.839.6748
FAQ
When will Zenas BioPharma (ZBIO) present at the Citi Biopharma Back to School Conference?
Zenas BioPharma is scheduled to present at the Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ET. The presentation will be available via webcast through the company’s website.
What is the date and time of Zenas BioPharma’s presentation at the Morgan Stanley Global Healthcare Conference 2026?
Zenas BioPharma plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 4:05 p.m. ET. Investors can access the live webcast and replay from the company’s website.
When is Zenas BioPharma presenting at the H.C. Wainwright 28th Annual Global Investment Conference?
The company is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Wednesday, September 16, 2026, at 8:00 a.m. ET. A live webcast and archived replay will be hosted on Zenas BioPharma’s website.
How can investors access the Zenas BioPharma (ZBIO) conference webcasts and replays?
Live webcasts and archived replays of Zenas BioPharma’s September 2026 conference presentations will be available under “Events and Presentations” in the Investor & Media Relations section of the company’s website.